Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Epidermis”

1,259 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,259 results

Testing effectiveness (Phase 2)Looking for participantsNCT05983107
What this trial is testing

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Who this might be right for
HR+/HER2- Advanced Breast CancerTargeted Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 102
Testing effectiveness (Phase 2)Active Not RecruitingNCT05262400
What this trial is testing

Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

Who this might be right for
Breast CancerSolid Tumors
Pfizer 235
Testing effectiveness (Phase 2)UnknownNCT01732276
What this trial is testing

The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Jiangmen Central Hospital 50
Large-scale testing (Phase 3)Looking for participantsNCT06340568
What this trial is testing

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

Who this might be right for
Endometrial Cancer
BioNTech SE 480
Testing effectiveness (Phase 2)Study completedNCT01885013
What this trial is testing

Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st Line Treatment of HER2 Neg. Metastatic Breast Cancer Patients

Who this might be right for
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 126
Testing effectiveness (Phase 2)UnknownNCT02967497
What this trial is testing

Clinical Study of YQ1 Plus Cisplatin-based Chemotherapy in Advanced NSCLC EGFR Wild Type

Who this might be right for
Epithelial Growth Factor Receptor Negative Non-small Cell Lung Cancer
Taipei Veterans General Hospital, Taiwan 56
Early research (Phase 1)Ended earlyNCT03255083
What this trial is testing

DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Daiichi Sankyo 13
Testing effectiveness (Phase 2)Looking for participantsNCT07326566
What this trial is testing

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Who this might be right for
Glioblastoma (GBM)Newly Diagnosed GlioblastomaGBM+4 more
Black Diamond Therapeutics, Inc. 162
Testing effectiveness (Phase 2)UnknownNCT06470672
What this trial is testing

Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Advanced Breast CancerHormone-receptor-positive Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast
Fudan University 32
Testing effectiveness (Phase 2)Ended earlyNCT02770014
What this trial is testing

Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

Who this might be right for
Epidermal Growth Factor ReceptorNon-Small Cell Lung Cancer
Dana-Farber Cancer Institute 43
Large-scale testing (Phase 3)Study completedNCT01774721
What this trial is testing

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Who this might be right for
Non-small Cell Lung Cancer With EGFR-Activating Mutations
Pfizer 452
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06545695
What this trial is testing

Epidermal Growth Factor Receptor Inhibition for Keratinopathies

Who this might be right for
Epidermolytic IchthyosisPalmoplantar KeratodermaPachyonychia Congenita
Northwestern University 44
Not applicableStudy completedNCT05711303
What this trial is testing

Study to Investigate the Effect of Superba Boost on the Skin

Who this might be right for
Trans-epidermal Water Loss
Atlantia Food Clinical Trials 70
Early research (Phase 1)Study completedNCT02476539
What this trial is testing

Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer

Who this might be right for
HER2 Positive Breast Cancer
Tianjin Hemay Pharmaceutical Co., Ltd 28
Large-scale testing (Phase 3)Ended earlyNCT03419403
What this trial is testing

UNITE Study: Understanding New Interventions With GBM ThErapy

Who this might be right for
Glioblastoma Multiforme
AbbVie 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06586294
What this trial is testing

Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Akeso 294
Very early researchNot Yet RecruitingNCT07498595
What this trial is testing

TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC

Who this might be right for
EGFR-TKI-resistant Non-Small Cell Lung Cancer
Tianjin Medical University General Hospital 50
Large-scale testing (Phase 3)UnknownNCT03008109
What this trial is testing

Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC

Who this might be right for
Advanced CancerLung Cancer, Nonsmall Cell
Zaiwen Fan 80
Not applicableUnknownNCT02661009
What this trial is testing

Human EGFR Mutations Quantitative Detection Kit (Real-time Fluorescent PCR Method)

Who this might be right for
Non Small Cell Lung CancerEGFR-TKI Resistant MutationEGFR-TKI Sensitizing Mutation
GenoSaber 1,000
Large-scale testing (Phase 3)UnknownNCT04651439
What this trial is testing

Severe Bullous Drug Eruption and Filgrastim

Who this might be right for
Rare DiseasesToxic Epidermal Necrolyses
Hospices Civils de Lyon 42
Next Page